APPLICATIONS · DISEASE AREA · IMMUNOLOGY AND INFLAMMATION
Profile the immune response at the depth modern programmes demand
Immune biology is defined by complex cytokine and inflammatory signalling, from autoimmune disease and chronic inflammation through to infection severity. Much of that signalling sits at concentrations standard methods cannot resolve.
We measure it on validated multiplex endpoints, ultra-sensitive single-molecule assays and discovery-scale profiling, in one laboratory, with data in two weeks.
APPLICATIONS · DISEASE AREA · IMMUNOLOGY AND INFLAMMATION
Profile the immune response at the depth modern programmes demand
Immune biology is defined by complex cytokine and inflammatory signalling, from autoimmune disease and chronic inflammation through to infection severity. Much of that signalling sits at concentrations standard methods cannot resolve.
We measure it on validated multiplex endpoints, ultra-sensitive single-molecule assays and discovery-scale profiling, in one laboratory, with data in two weeks.
Validated endpoints and discovery depth in one laboratory
Validated endpoints and discovery depth in one laboratory
Validated endpoints and discovery depth in one laboratory
Data in two weeks
Data in two weeks
Data in two weeks
Up to 340 immune proteins in a single run
Up to 340 immune proteins in a single run
Up to 340 immune proteins in a single run
HTA licensed, GCP compliant
HTA licensed, GCP compliant
HTA licensed, GCP compliant
Send us your marker list
Tell us the cytokines, chemokines or immune markers that matter, your matrix, and your cohort size. We will tell you which platform covers them, where the sensitivity sits for your specific targets, and whether you need one platform or two. That reply comes within one working day.
WHY IT MATTERS
The immune system sits at the centre of disease biology
From autoimmune conditions to chronic inflammatory disease to the acute response driving infection severity, immune biology runs through nearly every programme we support.
It also poses a consistent analytical challenge. The biology is rarely one marker at one timepoint. It spans multiple immune pathways, several orders of magnitude in concentration and a time course. A cytokine that matters at day three may be undetectable at day one, and a marker that drives severity may sit three logs below the one that defines the endpoint.
That is why immune-response work spans one of the widest analytical ranges in translational research: from validated cytokine, chemokine, serology and immunogenicity endpoints already written into trial protocols, through to femtogram-level early-response signals and broad discovery profiling.
Most laboratories are built for one part of that range, so a programme that needs two parts usually ends up with two suppliers. We cover the full range in one laboratory.
WHY IT MATTERS
The immune system sits at the centre of disease biology
From autoimmune conditions to chronic inflammatory disease to the acute response driving infection severity, immune biology runs through nearly every programme we support.
It also poses a consistent analytical challenge. The biology is rarely one marker at one timepoint. It spans multiple immune pathways, several orders of magnitude in concentration and a time course. A cytokine that matters at day three may be undetectable at day one, and a marker that drives severity may sit three logs below the one that defines the endpoint.
That is why immune-response work spans one of the widest analytical ranges in translational research: from validated cytokine, chemokine, serology and immunogenicity endpoints already written into trial protocols, through to femtogram-level early-response signals and broad discovery profiling.
Most laboratories are built for one part of that range, so a programme that needs two parts usually ends up with two suppliers. We cover the full range in one laboratory.
WHY IT MATTERS
The immune system sits at the centre of disease biology
From autoimmune conditions to chronic inflammatory disease to the acute response driving infection severity, immune biology runs through nearly every programme we support.
It also poses a consistent analytical challenge. The biology is rarely one marker at one timepoint. It spans multiple immune pathways, several orders of magnitude in concentration and a time course. A cytokine that matters at day three may be undetectable at day one, and a marker that drives severity may sit three logs below the one that defines the endpoint.
That is why immune-response work spans one of the widest analytical ranges in translational research: from validated cytokine, chemokine, serology and immunogenicity endpoints already written into trial protocols, through to femtogram-level early-response signals and broad discovery profiling.
Most laboratories are built for one part of that range, so a programme that needs two parts usually ends up with two suppliers. We cover the full range in one laboratory.
Typical applications
Typical applications
Inflammation and immune-mediated disease
Immunotherapy and immune activation
Vaccines, immunogenicity and infection
Autoimmunity biomarker profiling
Chronic inflammatory disease
Transplantation immunology
Inflammation and immune-mediated disease
Immunotherapy and immune activation
Vaccines, immunogenicity and infection
Autoimmunity biomarker profiling
Chronic inflammatory disease
Transplantation immunology
HOW IT WORKS
Validated endpoints and discovery depth in one workflow
Immune programmes often need two analytical modes at the same time: validated, reproducible tools for endpoints already written into trial protocols, and ultra-sensitive discovery platforms for biology that has not yet become standard.
Running both here keeps discovery, validation and follow-on measurement in the same analytical environment – same samples, same QC framework.
Profile amyloid, multiple tau species, NfL, GFAP, synaptic proteins and neuroinflammatory mediators from a single CSF or plasma draw.
Used in Alzheimer’s disease, ALS, frontotemporal dementia, Parkinson’s disease, Lewy body disease and rare neurological disorders.
How this usually runs
Broad NULISA profiling identifies the immune signals that separate responders from non-responders, or severe from mild. Then the programme narrows.
The markers carrying the signal move onto MSD for validated multiplex measurement, or onto Simoa where a single marker needs the deepest sensitivity and the strongest literature record. That validated set then supports the endpoint, the monitoring or the stratification.
All of this happens in one laboratory, so moving between stages never means a new supplier, a new chain of custody or inter-lab differences to reconcile at analysis.
The practical detail
Turnaround
Two weeks from sample receipt, confirmed in writing at quote
Quote
Within one working day of receiving your marker list
Up to 1,000-fold greater than conventional ELISA.
Femtogram-per-millilitre for many targets.
SR-X performance figures confirmed per assay at scoping
Sample confirmation
Receipt and condition confirmed within two working days, before anything is consumed
Receipt and condition confirmed within two working days, before anything is consumed
Sample volume
NULISAseq needs 25 µL of sample and NULISAqpcr needs 35 µL. Ship about 10 µL more than the assay requires, so 35 µL for NULISAseq and 45 µL for NULISAqpcr, which covers dead volume and leaves enough for a repeat. MSD and Simoa requirements are assay-dependent
NULISAseq needs 25 µL of sample and NULISAqpcr needs 35 µL. Ship about 10 µL more than the assay requires, so 35 µL for NULISAseq and 45 µL for NULISAqpcr, which covers dead volume and leaves enough for a repeat. MSD and Simoa requirements are assay-dependent
Matrices
Plasma, serum, CSF, urine, cell-culture supernatant and tissue lysate. Specialist matrices including BAL, sputum, nasal lining fluid, EBC and interstitial fluid scoped for feasibility
Plasma, serum, CSF, urine, cell-culture supernatant and tissue lysate. Specialist matrices including BAL, sputum, nasal lining fluid, EBC and interstitial fluid scoped for feasibility
Cohort size
Dozens to tens of thousands of samples
Dozens to tens of thousands of samples
Data output
Relative quantification in NPQ units for NULISAseq panels. Absolute concentrations in pg/mL for MSD, Simoa and the 250 AQ panel
Relative quantification in NPQ units for NULISAseq panels. Absolute concentrations in pg/mL for MSD, Simoa and the 250 AQ panel
Deliverables
Normalised data, QC metrics and run documentation. Bioinformatic analysis available
Normalised data, QC metrics and run documentation. Bioinformatic analysis available
Quality framework
HTA licence 12818. GCP-compliant workflows. Aligned to ISO 15189, with accreditation in progress
HTA licence 12818. GCP-compliant workflows. Aligned to ISO 15189, with accreditation in progress
Regulatory status
For research use only. Not for use in diagnostic procedures
Regulatory status
For research use only. Not for use in diagnostic procedures
For research use only. Not for use in diagnostic procedures
340 immune targets from a single small sample
The NULISAseq Inflammation Panel 250 and Immune 340 Panel measure hundreds of cytokines, chemokines and immune mediators from a single small-volume sample – enough breadth to see the whole response, not just the markers you expected.
Where a target needs absolute quantification, we confirm it on Simoa or MSD in the same laboratory, under the same chain of custody.
We run Simoa on the SR-X alongside NULISA, MSD and sequencing.
All of them are ours, so the recommendation you get is a scientific one. If your target is better served by NULISA or MSD we will say so, and the work stays with us either way.
Homebrew development means we are not limited to the catalogue.
Where no commercial Simoa assay exists for your target, we can build one.
THE ALTHEOME DIFFERENCE
Why immunology programmes work with us
The full analytical range in one place
Platform advice shaped by your biology
Specialist matrices
Speed as a design principle
Senior scientific oversight
Analysis by the people who ran the assay
Validated multiplex endpoints, ultra-sensitive single-molecule measurement, discovery-scale profiling, custom development and transcriptomics.
Immune work needs more than one of these more often than not.
THE ALTHEOME DIFFERENCE
Why immunology programmes work with us
The full analytical range in one place
Platform advice shaped by your biology
Specialist matrices
Speed as a design principle
Senior scientific oversight
Analysis by the people who ran the assay
Validated multiplex endpoints, ultra-sensitive single-molecule measurement, discovery-scale profiling, custom development and transcriptomics.
Immune work needs more than one of these more often than not.
THE ALTHEOME DIFFERENCE
Why immunology programmes work with us
The full analytical range in one place
Platform advice shaped by your biology
Specialist matrices
Speed as a design principle
Senior scientific oversight
Analysis by the people who ran the assay
Validated multiplex endpoints, ultra-sensitive single-molecule measurement, discovery-scale profiling, custom development and transcriptomics.
Immune work needs more than one of these more often than not.
Tell us about your study
Send us your markers, matrix and cohort size.
A senior scientist will tell you which platform fits, including when the answer is fewer platforms than you expected.
Running a multi-study programme? You will hear from us within one working day.
Running a multi-study programme? You will hear from us within one working day.
Explore a partnership
Explore a partnership